Hematology 2018 provides review articles from the Education Program at the 2018 ASH Annual Meeting. In this publication, each chapter relates to a different session presented at the meeting, spanning the spectrum from basic discovery and disease pathogenesis to the clinical application at the bedside.
This activity is supported by educational grants from AstraZeneca and Novartis Oncology
In patients with acute lymphoblastic leukemia (ALL), treatment response is increasingly evaluated with minimal residual disease (MRD) assays.
Leukocytosis, or elevated WBC count, is a commonly encountered laboratory finding. Distinguishing malignant from benign leukocytosis is a critical step in the care of a patient, which initiates a vastly different decision tree.
Neutropenia is defined as the reduction in the absolute number of neutrophils in the blood circulation. Acute neutropenia is a relatively frequent finding, whereas disorders of production of neutrophils are quite rare.